

RESEARCH MONOGRAPH . COMPOUND PROFILE

Schisandrin B

A principal bioactive dibenzocyclooctadiene lignan isolated from the fruit of Schisandra chinensis, distinguished by potent Nrf2-dependent antioxidant induction, NF-κB suppression, mitochondrial protective activity, and hepatoprotective efficacy across multiple preclinical models of chemical, ischemic, and metabolic liver injury.

DOCUMENT	KDC-MN-1610
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Dibenzocyclooctadiene lignan with pleiotropic antioxidant, hepatoprotective, anti-inflammatory, and cytoprotective activity

RESEARCH USE ONLY

ABSTRACT

Schisandrin B (Sch B), also designated gamma-schisandrin, is the most pharmacologically characterized dibenzocyclooctadiene lignan isolated from the dried ripe fruit of *Schisandra chinensis* (Turcz.) Baill., a climbing vine of the family Schisandraceae with a history of use in traditional Chinese medicine spanning more than two millennia under the name wuweizi (five-flavor berry). Among the more than 30 structurally related lignans present in the *Schisandra* fruit, Schisandrin B has attracted the greatest research attention owing to a convergence of potent antioxidant, anti-inflammatory, hepatoprotective, cardioprotective, and neuroprotective activities demonstrated across a substantial body of in vitro and in vivo preclinical literature. The compound acts principally through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor and its downstream antioxidant response element (ARE)-dependent gene program, producing upregulation of glutathione S-transferase, heme oxygenase-1, NAD(P)H:quinone oxidoreductase 1, superoxide dismutase, and catalase. Concurrently, Schisandrin B suppresses NF- κ B nuclear translocation and downstream proinflammatory cytokine expression (tumor necrosis factor α , interleukin-1 β , interleukin-6) through inhibition of I κ B- α degradation and suppression of MAPK cascade phosphorylation at c-Raf, MEK, ERK, JNK, and p38 nodes. Additional characterized mechanisms include enhancement of mitochondrial glutathione antioxidant status and heat shock protein induction, activation of the SIRT1/PI3K/Akt and AMPK/mTOR signaling axes, suppression of ferroptosis through upregulation of SLC7A11, GPX4, and FTH1, and modulation of pregnane X receptor (PXR)-mediated bile acid

metabolism. The hepatoprotective activity is the best-validated pharmacological property: Schisandrin B protects against carbon tetrachloride-induced hepatotoxicity, D-galactosamine-induced hepatocyte apoptosis, ischemia-reperfusion liver injury, doxorubicin and pirarubicin-induced hepatotoxicity, acetaminophen hepatotoxicity, cholestatic liver injury, and metabolic-associated fatty liver disease in rodent models, with efficacy demonstrated at oral doses typically in the range of 25 to 100 mg/kg in mice and rats. The compound also exhibits preclinical cardioprotective activity against doxorubicin cardiotoxicity and angiotensin II-induced cardiac fibrosis, and neuroprotective activity against amyloid-beta-induced neuronal dysfunction, scopolamine-induced amnesia, and cisplatin-induced neurotoxicity. Pharmacokinetic characterization in rats demonstrates oral bioavailability of approximately 19 to 55 percent (with sex-dependent variation), extensive hepatic accumulation consistent with its liver-protective profile, a double-peak absorption curve suggestive of enterohepatic circulation, and linear pharmacokinetics across the 10 to 40 mg/kg oral dose range. Schisandrin B is a potent, dose-dependent, noncompetitive inhibitor of CYP3A activity (K_i approximately 16.6 mg/kg in vivo) and inhibits P-glycoprotein-mediated efflux, producing clinically relevant herb-drug interactions with CYP3A substrates including midazolam, tacrolimus, and sirolimus. The compound has not been evaluated in human clinical trials as an isolated entity; all pharmacological and safety characterization derives from preclinical studies and from clinical experience with *Schisandra chinensis* fruit extracts and the semi-synthetic derivative bifendate (dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate). Preclinical toxicology in dogs has demonstrated dose-dependent plasma

accumulation on repeated administration, and in vitro studies at high concentrations have identified paradoxical hepatotoxicity in mouse hepatocytes and macrophages, indicating that the therapeutic window requires careful characterization before clinical translation. This monograph documents the chemistry, stereochemistry, and botanical source of Schisandrin B; the molecular pharmacology across Nrf2, NF-kB, SIRT1, AMPK, and mitochondrial mechanisms; the preclinical pharmacokinetic profile; the comprehensive preclinical evidence base across hepatoprotective, cardioprotective, neuroprotective, anti-inflammatory, and antitumor indications; sourcing and quality verification; reconstitution and handling; stack interactions with emphasis on CYP3A and P-glycoprotein; adverse events and safety signals including dose-dependent hepatotoxicity; and a comparative assessment of five related hepatoprotective or Nrf2-activating compounds against Schisandrin B on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Common name: Schisandrin B.

Synonyms: gamma-Schisandrin, Sch B, Wuweizisu B, Schizandrin B, deoxyschizandrin.

Chemical Abstracts Service registry number: 61281-37-6 (racemic or unspecified stereochemistry). A separate CAS number, 82467-52-5, is assigned to the (+)-Schisandrin B enantiomer in some supplier catalogs.

PubChem compound identifier: CID 108130.

International Union of Pure and Applied Chemistry name: rel-(6R,7S,13aR)-5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f][1,3]benzodioxole.

1.2 Structural class and chemistry

Schisandrin B is a dibenzocyclooctadiene lignan, a structural subclass of the broader lignan family characterized by a biphenyl unit bridged by an eight-membered carbocyclic ring. The dibenzocyclooctadiene skeleton is the defining structural motif of the Schisandra lignans and distinguishes them from other lignan classes (furanolignans, aryltetralin lignans, dibenzylbutane lignans) found in other plant families [1, 2].

Molecular formula: C₂₃H₂₈O₆.

Molecular weight: 400.47 g/mol.

Exact mass: 400.1886 g/mol (monoisotopic).

Physical properties: White to off-white crystalline powder. Soluble in dimethyl sulfoxide (DMSO), ethanol, methanol, and chloroform; sparingly soluble in water. Melting point is approximately 115 to 120 degrees Celsius. The compound absorbs ultraviolet light with maxima in the 215 to 254 nm range, consistent with the biphenyl chromophore.

Stereochemistry: Schisandrin B contains three stereogenic elements: two contiguous stereocenters at C-6 and C-7 of the cyclooctadiene ring (bearing methyl substituents) and an axis of chirality at the biphenyl bond that is conformationally restricted by the eight-membered bridge. The natural product isolated from *Schisandra chinensis* is reported in the rel-(6R,7S,13aR) configuration. The compound is supplied commercially in both racemic and enantiomerically defined forms; investigators should confirm stereochemical identity when pharmacological specificity is under investigation.

Functional groups: The molecule contains four methoxy groups (positions 1, 2, 3, and 13 of the biphenyl system) and a methylenedioxy bridge (forming the 1,3-benzodioxole ring on one aromatic nucleus). The cyclooctadiene ring carries two methyl groups at positions 6 and 7 in a trans-diaxial or trans-diequatorial arrangement depending on conformational state. The absence of free hydroxyl groups (in contrast to some other *Schisandra* lignans such as gomisins) contributes to the lipophilicity and the limited aqueous solubility of the compound.

1.3 Botanical source and isolation

Schisandrin B is isolated from the dried ripe fruit of *Schisandra chinensis* (Turcz.) Baill. (family Schisandraceae), a deciduous climbing vine native to northeast China, the Russian Far East, Korea, and Japan [3]. The fruit is known in Chinese pharmacopoeia as wuweizi (five-flavor berry) and has been used in traditional Chinese medicine for more than 2000 years as a tonic, astringent, and liver-protective agent. The Chinese Pharmacopoeia recognizes two species under the common name wuweizi: *Schisandra chinensis* (northern wuweizi) and *Schisandra sphenanthera* (southern wuweizi), which differ in lignan composition and pharmacological profile [4].

Schisandrin B is one of the principal dibenzocyclooctadiene lignans in the fruit, along with schisandrin (schisandrin A), schisandrin C, schisandrol A, schisandrol B, gomisins A, B, C, G, J, and N. Quantitative analysis by high-performance liquid chromatography (HPLC) has identified schisandrol A as the most abundant lignan in the flower, pulp, and seed, while schisandrin B is a major lignan present in the pulp and seed fractions [5]. Typical content of schisandrin B in the dried fruit ranges from 0.1 to 0.5 percent by weight, depending on cultivar, harvest time, geographic origin, and post-harvest processing.

Industrial isolation of schisandrin B from the crude fruit extract employs solvent extraction (ethanol or methanol), liquid-liquid partitioning, and chromatographic purification (silica gel column chromatography, preparative HPLC, or high-speed counter-current chromatography). Synthetic routes to the dibenzocyclooctadiene skeleton have been reported in the medicinal chemistry literature but are not the standard commercial source; the compound is predominantly obtained by extraction from plant material.

1.4 Semi-synthetic derivative: bifendate

A historically important semi-synthetic derivative of Schisandrin B is bifendate (dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate, also known as DDB or biphenyl dimethyl dicarboxylate), a simplified biphenyl analog developed in China in the 1970s and 1980s as a hepatoprotective agent for the treatment of viral hepatitis [6]. Bifendate was designed by structural simplification of the Schisandrin B scaffold, retaining the biphenyl core with methoxy and methylenedioxy substituents while removing the cyclooctadiene bridge. The compound has been used clinically in China, Japan, Korea, and other Asian jurisdictions for the treatment of hepatitis B and drug-induced liver injury. The clinical experience with bifendate provides indirect pharmacological validation of the Schisandrin B structural class, though the two compounds differ substantially in their complete pharmacological profiles.

2. Abstract

Schisandrin B (gamma-schisandrin, CAS 61281-37-6) is the most extensively studied dibenzocyclooctadiene lignan from *Schisandra chinensis*, a traditional Chinese medicinal plant with a 2000-year history of use as a liver tonic and adaptogen. The compound operates through a convergent molecular pharmacology centered on the Nrf2/ARE antioxidant axis and the NF- κ B inflammatory axis, with additional characterized activities at SIRT1, AMPK/mTOR, PXR, and mitochondrial targets [7, 8, 9].

The hepatoprotective activity is the most robustly validated pharmacological property. In rodent models, Schisandrin B protects against liver injury induced by carbon tetrachloride, D-galactosamine, acetaminophen, ischemia-reperfusion, doxorubicin, pirarubicin, alpha-naphthylisothiocyanate (ANIT)-induced cholestasis, high-fat diet, and methionine-choline deficient diet, with effective oral doses typically in the 25 to 100 mg/kg range in mice and rats [10, 11, 12, 13, 14]. The mechanism is composite: Schisandrin B enhances mitochondrial glutathione antioxidant capacity, induces heat shock proteins (HSP25, HSP70), activates Nrf2 with downstream upregulation of phase II detoxification enzymes, suppresses NF- κ B-driven hepatic inflammation, attenuates hepatic stellate cell activation and fibrogenesis through TGF-beta/Smad pathway modulation, inhibits ferroptosis through GPX4 and SLC7A11 upregulation, and promotes protective autophagy through AMPK/mTOR signaling [15, 16, 17].

Cardioprotective activity has been demonstrated against doxorubicin-induced cardiotoxicity (through MAPK/p53 signaling inhibition and oxidative stress reduction) and against angiotensin II-induced cardiac fibrosis and atrial fibrillation (through SIRT1 pathway activation and ferroptosis suppression) [18, 19, 20]. Neuroprotective activity has been characterized against amyloid-beta-induced oxidative stress and neuroinflammation (through RAGE/NF- κ B/MAPK inhibition and HSP/Beclin upregulation), against scopolamine-induced cognitive deficit, and against cisplatin-induced neurotoxicity [21, 22].

The antitumor activity of Schisandrin B has been investigated across multiple cancer types in preclinical models, including colon cancer, hepatocellular carcinoma, breast cancer, and gastric cancer. Mechanisms include cell cycle arrest,

apoptosis induction through unfolded protein response and CHOP upregulation, inhibition of proliferation and metastasis, and modulation of exosomal fibronectin 1 expression [23, 24].

Pharmacokinetics in rats demonstrate moderate oral bioavailability (approximately 19 to 55 percent with sex-dependent variation), preferential hepatic accumulation, enterohepatic circulation (evidenced by double-peak absorption curves), and linear dose-proportionality across the 10 to 40 mg/kg range [25, 26]. The compound is a potent noncompetitive inhibitor of CYP3A (K_i approximately 16.6 mg/kg) and inhibits P-glycoprotein-mediated efflux, producing clinically significant interactions with CYP3A substrates including tacrolimus (40 percent dose reduction reported in transplant recipients receiving Schisandra extract), midazolam, and sirolimus [27, 28, 29].

No human clinical trials of isolated Schisandrin B have been reported. Clinical pharmacological experience is derived entirely from Schisandra chinensis fruit extracts and from the semi-synthetic derivative bifendate. Preclinical safety characterization has identified dose-dependent hepatotoxicity at high concentrations in vitro (a paradoxical "double-edged sword" profile), dose-dependent plasma accumulation in dogs on repeated administration, and potential adverse effects on hepatic and renal function at supratherapeutic exposures [30, 31]. The compound is currently positioned as a preclinical research tool and a candidate for clinical translation in hepatoprotective and cytoprotective applications, pending systematic toxicology, formulation optimization, and human pharmacokinetic characterization.

3. Discovery and Development History

3.1 Traditional use of *Schisandra chinensis*

The use of *Schisandra chinensis* fruit in East Asian medicine predates the modern isolation of its lignan constituents by more than two millennia. The earliest recorded pharmacological descriptions appear in the *Shennong Bencao Jing* (Divine Farmer's Classic of Materia Medica), compiled approximately in the first or second century CE, which classifies wuweizi as an upper-grade tonic herb with applications in cough suppression, qi replenishment, astringency, and general vitality enhancement [3]. The fruit's Chinese name, wuweizi (five-flavor berry), reflects the traditional observation that it combines sweet, sour, salty, bitter, and pungent tastes, a property attributed to its complex phytochemical composition.

In the traditional Chinese medical framework, wuweizi was prescribed primarily for conditions of the lung, kidney, and liver meridians, including chronic cough, nocturnal emission, urinary frequency, spontaneous sweating, chronic diarrhea, and debility following prolonged illness. The liver-protective application, which would later become the most pharmacologically validated property of its lignan constituents, was recognized in the traditional literature as an ability to "astringe the essence and nourish the liver."

3.2 Modern isolation and structural characterization

The systematic phytochemical investigation of *Schisandra chinensis* began in the mid-twentieth century, driven by the observation that crude *Schisandra* extracts reduced elevated serum transaminase levels in patients with viral hepatitis in Chinese clinical practice. The isolation and structural characterization of the principal dibenzocyclooctadiene lignans, including schisandrin (schisandrin A), schisandrin B, schisandrin C, schisandrol A, schisandrol B, and the gomisins, was accomplished through a series of studies published between the 1960s and 1980s by Chinese and Japanese research groups [1, 2].

Schisandrin B was identified as a distinct chemical entity with the molecular formula $C_{23}H_{28}O_6$ and characterized by nuclear magnetic resonance spectroscopy, mass spectrometry, and X-ray crystallography. The absolute configuration was as-

signed as (6R,7S,13aR) for the natural product isolated from the northern species *Schisandra chinensis*.

3.3 Development of bifendate

The clinical interest in Schisandrin B and related lignans was catalyzed by the development of bifendate (DDB) in China during the 1970s. Chinese pharmaceutical chemists, motivated by the clinical observation that *Schisandra* extract reduced serum alanine aminotransferase (ALT) levels in hepatitis patients, designed bifendate as a structurally simplified synthetic analog of the Schisandrin B biphenyl core [6]. Bifendate was approved in China for the treatment of viral hepatitis and has been used clinically in multiple Asian jurisdictions since the 1980s. The clinical success of bifendate validated the hepatoprotective potential of the dibenzocyclooctadiene structural class and stimulated further pharmacological investigation of the parent natural product Schisandrin B.

3.4 Modern pharmacological characterization

The modern pharmacological literature on Schisandrin B began to expand substantially in the early 2000s, driven by advances in molecular biology that permitted mechanistic characterization of the antioxidant and anti-inflammatory pathways. The identification of Nrf2 as the principal transcriptional mediator of the Schisandrin B antioxidant response, reported by multiple groups between 2005 and 2012, provided a unifying molecular mechanism for the hepatoprotective, cardioprotective, and cytoprotective activities that had been observed empirically [7, 8]. The demonstration by Checker et al. (2012) that Schisandrin B exhibits anti-inflammatory activity through modulation of both Nrf2 and NF- κ B in lymphocytes established the dual-axis pharmacological model that is now the standard mechanistic framework for the compound [9].

Subsequent expansion of the preclinical literature has encompassed hepatic ischemia-reperfusion injury, nonalcoholic fatty liver disease, cardiac fibrosis, neurodegeneration, asthma, and antitumor applications, producing a research record of several hundred published studies as of the most recent monograph revision. The compound has not progressed to human clinical trials as an isolated entity, and the current developmental positioning is that of a well-characterized preclinical candidate with strong mechanistic rationale and a need for systematic formulation, toxicology, and clinical pharmacokinetic studies.

4. Mechanism of Action

Schisandrin B is a pleiotropic lignan with multiple characterized molecular targets. Its pharmacological activity reflects the convergent modulation of redox-sensitive transcription factors, stress-responsive kinase cascades, and mitochondrial protective mechanisms. The principal molecular activities, organized by pathway, are described below.

4.1 Nrf2/ARE antioxidant pathway activation

The nuclear factor erythroid 2-related factor 2 (Nrf2) is the master transcriptional regulator of the cellular antioxidant response. Under basal conditions, Nrf2 is sequestered in the cytoplasm by its negative regulator Keap1 (Kelch-like ECH-associated protein 1), which targets Nrf2 for ubiquitination and proteasomal degradation. Electrophilic or oxidative stress modifies reactive cysteine residues on Keap1, releasing Nrf2 for nuclear translocation and binding to the antioxidant response element (ARE) in the promoter regions of cytoprotective genes [7].

Schisandrin B activates Nrf2 nuclear translocation through a mechanism that involves alteration of the cellular redox status. In lymphocytes, hepatocytes, endothelial cells, and airway epithelial cells, Schisandrin B enhances reactive oxygen species (ROS) levels transiently and alters the glutathione/glutathione disulfide (GSH/GSSG) ratio, triggering Keap1 modification and Nrf2 release [8, 9]. The downstream consequence is transcriptional upregulation of ARE-dependent genes including heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione S-transferase (GST), superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), and the glutamate-cysteine ligase catalytic subunit (GCLC, the rate-limiting enzyme in glutathione biosynthesis).

The net pharmacological effect is an enhancement of the cellular antioxidant defense that is sustained beyond the initial transient ROS elevation. This "hormetic" antioxidant mechanism, in which a mild pro-oxidant stimulus induces a disproportionately large antioxidant response, is the molecular basis for the hepatoprotective, cardioprotective, and neuroprotective activities observed in preclinical models.

4.2 NF- κ B inflammatory pathway suppression

The nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) is the principal transcriptional regulator of inflammatory gene expression. Schisandrin B suppresses NF- κ B activation through inhibition of I κ B- α degradation, which prevents the nuclear translocation of the p65/p50 NF- κ B heterodimer [9]. The downstream consequence is reduced transcription of proinflammatory mediators including tumor necrosis factor α (TNF- α), interleukin-1 β (IL-1 β), interleukin-6 (IL-6), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2).

The NF- κ B suppression by Schisandrin B is mechanistically linked to the Nrf2 activation: Checker et al. (2012) demonstrated that the anti-inflammatory effects of Schisandrin B in lymphocytes are significantly abrogated by pharmacological inhibitors of Nrf2 and HO-1, indicating that the Nrf2/HO-1 pathway is upstream of or necessary for the NF- κ B suppression [9]. This dual-axis modulation (Nrf2 upregulation coupled to NF- κ B downregulation) is a hallmark of the Schisandrin B pharmacology and distinguishes it from compounds that act on either pathway alone.

Additionally, Schisandrin B inhibits mitogen-induced phosphorylation of c-Raf, MEK, ERK, JNK, and p38 in the MAPK cascade, providing a second mechanistic route to inflammatory suppression that operates in parallel with the NF- κ B pathway [9].

4.3 Mitochondrial protection

Schisandrin B enhances mitochondrial glutathione antioxidant status and induces heat shock proteins (HSP25 and HSP70) in hepatic tissue, a mechanism first characterized by Ip et al. (2000) in the context of carbon tetrachloride-induced hepatotoxicity [10]. The compound decreases the sensitivity of mitochondria to calcium ion-induced permeability transition, a critical event in mitochondrial-mediated apoptosis and necrosis [32]. This mitochondrial protective activity is independent of the Nrf2/ARE nuclear transcriptional program and represents a direct organellar mechanism of cytoprotection.

Recent investigations have extended the mitochondrial mechanism to include regulation of Sirt3 (mitochondrial sirtuin 3), with Schisandrin B improving mitochondrial function and inhibiting apoptosis in hippocampal HT22 cells through Sirt3 protein modulation [33].

4.4 SIRT1/PI3K/Akt signaling

Schisandrin B activates the sirtuin 1 (SIRT1) deacetylase and its downstream PI3K/Akt signaling axis. In models of angiotensin II-induced cardiac fibrosis, Schisandrin B increased SIRT1 expression while decreasing cardiac fibrosis markers (collagen I, collagen III, alpha-smooth muscle actin) and lowering phosphorylated PI3K and Akt [19, 20]. The SIRT1 pathway activation also mediates suppression of ferroptosis through upregulation of SLC7A11 (the cystine/glutamate antiporter), GPX4 (glutathione peroxidase 4), and FTH1 (ferritin heavy chain 1), which are key proteins in the ferroptosis defense machinery.

4.5 AMPK/mTOR autophagy signaling

Schisandrin B activates AMP-activated protein kinase (AMPK) and suppresses mechanistic target of rapamycin (mTOR) signaling, promoting protective autophagy [16]. In models of hepatic steatosis and metabolic-associated fatty liver disease (MAFLD), this mechanism promotes fatty acid oxidation, reduces lipid accumulation, and attenuates hepatocyte injury. The AMPK/Nrf2 signaling axis is also implicated in protection against hypoxia/reoxygenation injury in cardiac and hepatic tissues.

4.6 Pregnane X receptor modulation

Schisandrin B has been identified as a modulator of the pregnane X receptor (PXR), a nuclear receptor that regulates bile acid metabolism and detoxification gene expression in the liver [14]. In models of ANIT-induced cholestatic liver injury, Schisandrin B enhanced bile acid metabolism through PXR-mediated dual pathways, providing a mechanism for its cholestatic liver-protective activity that is distinct from the Nrf2/NF- κ B axis.

4.7 Composite pharmacology

The composite pharmacology of Schisandrin B is therefore multi-targeted: Nrf2/ARE activation for antioxidant defense; NF- κ B and MAPK suppression for anti-inflammatory activity; mitochondrial GSH enhancement and HSP induction for direct organellar protection; SIRT1/Akt activation for anti-fibrotic and anti-ferroptotic activity; AMPK/mTOR modulation for pro-autophagic and lipid-metabolic activity; and PXR modulation for bile acid homeostasis. This convergent, multi-pathway

pharmacology is consistent with the observed pleiotropic efficacy across diverse models of tissue injury and explains the compound's attractiveness as a candidate hepatoprotective and cytoprotective agent.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Schisandrin B is absorbed from the gastrointestinal tract after oral administration in rats, with oral bioavailability reported at approximately 55.0 percent in female rats and 19.3 percent in male rats, indicating substantial sex-dependent variation [25, 26]. The pharmacokinetic profile following oral administration exhibits a double-peak absorption curve, which is interpreted as evidence of enterohepatic circulation [25]. Time to first peak plasma concentration (T_{max1}) is approximately 0.5 to 1 hour, with a second peak (T_{max2}) at approximately 4 to 6 hours after oral dosing.

Schisandrin B exhibits linear pharmacokinetics within the tested oral dose range of 10, 20, and 40 mg/kg in rats, with dose-proportional increases in C_{max} and AUC [25]. The bioavailability of Schisandrin B administered as a component of the whole *Schisandra chinensis* extract may differ from that of the purified compound; one report indicated that the bioavailability of the related lignan schisandrol B was substantially higher when administered as the extract (68.1 percent) than as the purified monomer (18.7 percent), suggesting matrix effects from other fruit constituents [34].

5.2 Distribution

Following oral administration in rats, Schisandrin B distributes extensively to tissues, with the highest concentrations observed in the liver, followed by kidney, heart, lung, spleen, and brain [25, 26]. The preferential hepatic accumulation is pharmacologically significant: it concentrates the compound at the principal site of its therapeutic activity and is consistent with the robust hepatoprotective efficacy observed in animal models. Extensive distribution to adipose tissue and ovary has also been reported, consistent with the lipophilic character of the compound (calculated LogP approximately 4 to 5).

Maximal tissue concentrations are generally observed at approximately 1 hour after oral dosing, with subsequent decline over 12 to 24 hours. Brain penetration is confirmed, supporting the observed neuroprotective activity in central nervous system models, though brain concentrations are lower than hepatic concentrations.

Plasma protein binding data for Schisandrin B in the published literature are limited. The high lipophilicity of the compound (sparingly soluble in water, freely soluble in DMSO and organic solvents) suggests substantial protein binding, consistent with other highly lipophilic natural products.

5.3 Metabolism

Schisandrin B is metabolized in the liver, predominantly through cytochrome P450-mediated oxidation. The compound undergoes demethylation, hydroxylation, and subsequent conjugation (glucuronidation and sulfation) to produce polar metabolites suitable for renal and biliary excretion [25]. The specific CYP isoforms responsible for Schisandrin B metabolism have not been completely delineated, though the compound's potent inhibition of CYP3A activity suggests that CYP3A4/5 may participate in its own metabolism through a mechanism-based inhibition or competitive substrate interaction.

Excretion studies in rats demonstrate very low urinary, biliary, and fecal excretion of unchanged Schisandrin B, indicating that the compound is excreted predominantly in the form of metabolites [25]. The double-peak pharmacokinetic profile and the hepatic accumulation are consistent with enterohepatic circulation of either the parent compound or its metabolites.

5.4 Elimination

The elimination half-life of Schisandrin B in rats has been reported in the range of 4 to 12 hours after oral administration, depending on dose, sex, and analytical methodology [25, 26]. The relatively long apparent half-life, combined with hepatic accumulation and enterohepatic circulation, produces a pharmacokinetic profile compatible with once-daily or twice-daily dosing in chronic administration studies.

Renal excretion of unchanged compound is minimal. The principal elimination pathway is hepatic metabolism followed by renal and biliary excretion of metabolites.

5.5 Routes of administration

In preclinical studies, Schisandrin B has been administered by the following routes:

Oral gavage: The most common route in chronic efficacy and toxicology studies. Doses typically range from 10 to 100 mg/kg in mice and rats, administered as a suspension in 0.5 percent carboxymethylcellulose, in corn oil, or in a DMSO/PEG300/Tween 80 vehicle system.

Intraperitoneal injection: Used in acute pharmacological studies. Doses typically range from 10 to 80 mg/kg in mice, dissolved in DMSO or in DMSO-containing vehicles.

Intravenous injection: Used in pharmacokinetic studies for absolute bioavailability determination. Doses typically range from 2 to 10 mg/kg, dissolved in DMSO/saline mixtures.

Dietary supplementation: Schisandrin B has been incorporated into rodent chow at concentrations sufficient to deliver target daily doses in chronic feeding studies, particularly in models of metabolic liver disease and chemotherapy-induced organ toxicity [17].

No human routes of administration have been established for isolated Schisandrin B. Clinical experience with the structural class derives from oral Schisandra fruit extract preparations and from oral bifendate tablets.

5.6 Special populations

Pharmacokinetic data in special populations (pediatric, geriatric, renally or hepatically impaired) are not available for isolated Schisandrin B. The sex-dependent bioavailability difference observed in rats (55 percent female vs. 19 percent male) has not been mechanistically explained and may reflect differences in CYP expression, P-glycoprotein activity, or gastrointestinal physiology between sexes.

6. Preclinical Pharmacology

6.1 Hepatoprotective activity

The hepatoprotective activity of Schisandrin B is the best-characterized and most extensively replicated pharmacological property. The following models have produced positive results:

Carbon tetrachloride (CCl₄)-induced hepatotoxicity: Schisandrin B pretreatment at 1 to 3 mmol/kg (approximately 25 to 75 mg/kg) orally in mice protected against CCl₄-induced hepatotoxicity as measured by serum ALT, AST, and histological assessment. The mechanism involves enhancement of hepatic mitochondrial glutathione antioxidant status, induction of HSP25 and HSP70, and Nrf2/ARE-dependent antioxidant enzyme upregulation [10, 15].

CCl₄-induced liver fibrosis: In chronic CCl₄ models, Schisandrin B attenuated liver fibrosis through regulation of the Nrf2/ARE pathway and suppression of TGF-beta/Smad signaling, reducing collagen deposition, alpha-smooth muscle actin expression, and hepatic stellate cell activation [15].

D-Galactosamine (D-GalN)-induced hepatocyte apoptosis: Schisandrin B protected human L02 hepatocytes against D-GalN-induced apoptosis through modulation of the Bcl-2/Bax ratio, reducing caspase activation and maintaining mitochondrial membrane potential [12].

Hepatic ischemia-reperfusion injury: Schisandrin B ameliorated ischemia-reperfusion injury in rat liver through modulation of hepatocyte autophagy, reducing oxidative stress markers and inflammatory cytokine release [13].

Doxorubicin and pirarubicin-induced hepatotoxicity: Dietary Schisandrin B supplementation inhibited oxidative stress, reduced ferroptosis and lipid peroxidation, and prevented pirarubicin-induced hepatotoxicity in mice [17]. Schisandrin B also protected against doxorubicin-induced hepatotoxicity through enhancement of glutathione redox cycling [35].

Cholestatic liver injury (ANIT-induced): Schisandrin B targeted PXR to enhance bile acid metabolism and alleviate ANIT-induced cholestatic liver injury through dual metabolic pathways [14].

Metabolic-associated fatty liver disease (MAFLD): Schisandrin B alleviated lipid metabolism disorders and apoptosis in MAFLD models through modulation of PPARgamma-PCK1 and caspase-3 signaling, and through AMPK/mTOR-mediated autophagy induction [11, 16].

6.2 Cardioprotective activity

Schisandrin B prevents doxorubicin-induced cardiac dysfunction through modulation of DNA damage, oxidative stress, and inflammation by inhibition of MAPK/p53 signaling [18]. The compound also prevents doxorubicin-induced cardiotoxicity through enhancement of cardiac glutathione redox cycling.

In models of angiotensin II-induced cardiac fibrosis and atrial fibrillation, Schisandrin B activates the SIRT1 pathway, upregulates ferroptosis-protective proteins (SLC7A11, GPX4, FTH1), reduces pro-inflammatory cytokines, and suppresses cardiac fibrosis markers [19, 20].

6.3 Neuroprotective activity

Schisandrin B ameliorates amyloid-beta (A β)-induced oxidative stress and neuronal dysfunction through inhibition of the RAGE/NF-kB/MAPK signaling axis and upregulation of HSP/Beclin expression [21]. In the intracerebroventricular A β infusion model, Schisandrin B attenuated increases in oxidative and nitrosative stress, inflammatory markers (iNOS, COX-2, IL-1 β , IL-6, TNF- α), and DNA damage [21].

Protection against scopolamine-induced cognitive deficit and cisplatin-induced neurotoxicity has been reported in mouse models, with mechanisms involving antioxidant enzyme upregulation and anti-inflammatory activity [22]. Improvement of mitochondrial function through Sirt3 protein regulation has been demonstrated in hippocampal HT22 neuronal cells [33].

6.4 Anti-inflammatory activity

Beyond the organ-specific models described above, Schisandrin B exhibits anti-inflammatory activity in airway inflammation models (asthma), LPS-stimulated endothelial cells, and cigarette smoke-induced airway injury [36, 37, 38]. The mechanism in all models converges on NF- κ B/Nrf2 dual-axis modulation, with Nrf2/HO-1 activation being necessary for the full anti-inflammatory effect.

6.5 Antitumor activity

Preclinical antitumor activity of Schisandrin B has been reported in colon cancer (cell cycle arrest and apoptosis induction through CHOP/unfolded protein response), hepatocellular carcinoma (downregulation of exosomal fibronectin 1), breast cancer, and gastric cancer cell lines and xenograft models [23, 24]. The anti-tumor mechanisms are distinct from the cytoprotective mechanisms and involve pro-apoptotic rather than anti-apoptotic pathways, reflecting the context-dependent pharmacology of the compound in normal versus malignant cells.

7. Clinical Evidence Base

7.1 Isolated Schisandrin B

No clinical trials of isolated Schisandrin B in human subjects have been published as of the most recent monograph revision. All pharmacological and safety characterization of the pure compound derives from preclinical studies. Clinical translation of isolated Schisandrin B requires completion of systematic preclinical toxicology (including the recommended Good Laboratory Practice studies in two species), formulation development for human oral dosing, and Phase 1 human pharmacokinetic and safety studies.

7.2 *Schisandra chinensis* fruit extracts

Schisandra chinensis fruit extracts containing Schisandrin B as one of multiple active lignans have been used clinically in East Asian medicine for several decades, primarily for the treatment of viral hepatitis (particularly hepatitis B) and for the management of elevated serum transaminases of various etiologies [3, 6]. Clinical experience with standardized *Schisandra* extracts has demonstrated reduction of serum ALT levels in patients with chronic hepatitis and general tolerability at the doses used in clinical practice.

The clinical data with whole *Schisandra* extracts cannot be directly attributed to Schisandrin B specifically, as the extracts contain multiple bioactive lignans and other phytochemicals that may contribute to or modify the pharmacological effect. However, the clinical observations are consistent with the preclinical hepatoprotective profile of Schisandrin B and provide indirect support for clinical translation.

7.3 Bifendate clinical experience

Bifendate (DDB), the semi-synthetic biphenyl derivative of the Schisandrin B structural class, has been used clinically in China and other Asian jurisdictions since the 1980s for the treatment of hepatitis B and drug-induced liver injury [6]. The clinical evidence base for bifendate includes multiple controlled trials demonstrating re-

duction of serum ALT levels, though the clinical significance and long-term hepatic outcomes of isolated transaminase reduction have been debated. Bifendate experience provides structural-class-level clinical validation but does not substitute for direct Schisandrin B clinical characterization.

7.4 Clinical pharmacokinetic interactions

The clinically relevant herb-drug interaction between Schisandra preparations and CYP3A substrates has been documented in transplant recipients. Schisandra extract coadministration with tacrolimus in renal transplant recipients reduced the required tacrolimus dose by approximately 40 percent, consistent with CYP3A inhibition by Schisandra lignans including Schisandrin B [29]. Similar interactions have been reported with sirolimus and midazolam. These clinical pharmacokinetic observations confirm the *in vivo* CYP3A inhibitory potency of the Schisandra lignan class and inform the drug interaction profile relevant to any future clinical development of isolated Schisandrin B.

8. Sourcing and Quality Verification

Research-grade Schisandrin B is available from multiple chemical and natural product suppliers, including MedChemExpress, Selleckchem, Sigma-Aldrich, Cayman Chemical, TargetMol, InvivoChem, GlpBio, BOC Sciences, Santa Cruz Biotechnology, Biorbyt, and others. The compound is supplied as the racemic mixture (CAS 61281-37-6) or as the (+)-enantiomer (CAS 82467-52-5), typically at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as a white to off-white crystalline powder. Pricing is moderate, in the range of \$40 to \$250 per 50 mg of research-grade material at the time of monograph preparation.

Schisandrin B can also be obtained from standardized *Schisandra chinensis* fruit extracts, though the purity and concentration will vary by extraction method and vendor. For mechanistic and dose-response studies requiring precisely known concentrations, purified compound rather than crude extract is essential.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography (HPLC) area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (401.20 for [M+H]⁺ or 423.18 for [M+Na]⁺)
- Nuclear magnetic resonance (¹H-NMR and ¹³C-NMR) confirmation of structural identity, with characteristic chemical shifts for the methoxy groups (delta 3.5 to 4.0), methylenedioxy protons (delta 5.9 to 6.0), aromatic protons (delta 6.5 to 6.7), and cyclooctadiene methyl groups (delta 0.8 to 1.0)
- Optical rotation measurement for stereochemical confirmation when enantiomerically defined material is required
- Karl Fischer or loss-on-drying analysis for residual water content

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. Lot-to-lot variability in natural product isolates is expected, and on-receipt analytical confirmation is appropriate for any investigation where dose-response precision is important.

9. Reconstitution and Handling

Schisandrin B is sparingly soluble in water and requires organic solvent systems for reconstitution. Stock solutions are typically prepared in DMSO at concentrations of 10 to 100 mM (4 to 40 mg/mL) for in vitro applications. The compound is freely soluble in DMSO, ethanol, methanol, and chloroform.

In vitro preparation: Dissolve in DMSO to the desired stock concentration (typically 10 to 50 mM). Dilute into cell culture medium immediately before use; final DMSO concentration should not exceed 0.1 to 0.5 percent (v/v) to avoid vehicle-related cytotoxicity. Prepare vehicle control groups with matched DMSO concentrations.

In vivo preparation (aqueous vehicle): Dissolve in DMSO, then sequentially add PEG300, Tween 80, and sterile water or saline with thorough mixing and clarification at each step. A typical vehicle composition is 5 percent DMSO, 40 percent PEG300, 5 percent Tween 80, and 50 percent saline. The solution obtained at each step must be clear before adding the next solvent component.

In vivo preparation (oil vehicle): Dissolve in DMSO, then add corn oil or sesame oil with thorough mixing. Alternatively, suspend directly in 0.5 percent carboxymethylcellulose (CMC) sodium for oral gavage.

Storage: Store the solid compound at -20 degrees Celsius, protected from light and moisture, in a desiccated container. Stock solutions in DMSO should be stored at -80 degrees Celsius for up to 6 months or at -20 degrees Celsius for up to 1 month. Aliquot stock solutions for single-use to avoid repeated freeze-thaw cycles, which may reduce potency. Do not store aqueous dilutions; prepare fresh immediately before use.

Stability: The compound is stable as a solid under recommended storage conditions. Solutions in DMSO are stable at -80 degrees Celsius for at least 6 months. Light protection is recommended for both solid and solution forms. Aqueous solutions at neutral pH are expected to have limited stability and should be used within hours of preparation.

10. Stack Interactions and Combinations

Schisandrin B interacts with several drug classes and biological pathways. Investigators conducting research with Schisandrin B, especially in combination studies or in animals receiving concurrent pharmacotherapy, should consider:

CYP3A substrates: Schisandrin B is a potent, dose-dependent, noncompetitive inhibitor of CYP3A activity in vivo, with a K_i value of approximately 16.6 mg/kg in rats [27]. Oral administration of Schisandrin B for 3 days significantly altered the pharmacokinetics of midazolam (a CYP3A probe substrate), increasing midazolam AUC and C_{max} [27]. Clinically, Schisandra extract containing Schisandrin B reduced tacrolimus dose requirements by approximately 40 percent in transplant recipients [29]. Other CYP3A substrates potentially affected include cyclosporine, sirolimus, atorvastatin, simvastatin, nifedipine, amlodipine, and many protease inhibitors. Concurrent use of Schisandrin B with narrow-therapeutic-index CYP3A substrates requires dose monitoring.

CYP2C and CYP2B substrates: Schisandra lignans with methylenedioxyphenyl groups (including Schisandrin B) inhibit CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1 activities in a time- and concentration-dependent manner in human liver microsomes [28]. The clinical significance of these interactions for isolated Schisandrin B at achievable plasma concentrations has not been established but should be considered in combination studies.

P-glycoprotein substrates: Schisandrin B inhibits P-glycoprotein (ABCB1)-mediated efflux in intestinal cells and in P-glycoprotein-overexpressing cell lines [29]. A small clinical study demonstrated that Schisandra extract increases the peak concentration and overall exposure of talinolol, a P-glycoprotein probe substrate. This interaction may increase the bioavailability and tissue exposure of P-glycoprotein substrates including digoxin, fexofenadine, and certain chemotherapy agents.

UGT substrates: Schisandra lignans have been reported to inhibit selected uridine 5'-diphospho-glucuronosyltransferases (UGTs) in human liver microsomes, potentially affecting the clearance of compounds undergoing glucuronidation [28].

Antioxidant and Nrf2-activating compounds: Concurrent administration with other Nrf2 activators (sulforaphane, curcumin, resveratrol, bardoxolone methyl) may produce additive or synergistic antioxidant effects. The combination has not been systematically evaluated for safety and may potentially overshoot the optimal redox balance.

Chemotherapy agents: Schisandrin B has been studied as a cytoprotective adjunct to chemotherapy (protecting normal tissue from doxorubicin, pirarubicin, cisplatin, and 5-fluorouracil toxicity) [17, 18, 35]. The CYP3A and P-glycoprotein inhibition may also alter the pharmacokinetics of the chemotherapy agent itself, requiring careful dose adjustment.

Other hepatoprotective agents: Combination with silymarin, glycyrrhizin, ursodeoxycholic acid, or N-acetylcysteine may produce additive hepatoprotective effects through complementary mechanisms. No adverse pharmacokinetic or pharmacodynamic interactions have been reported, though systematic combination studies are limited.

11. Adverse Events and Safety Signal

11.1 Preclinical safety profile

Schisandrin B has been generally well tolerated in preclinical studies at the doses used for hepatoprotective and cytoprotective efficacy (typically 10 to 100 mg/kg orally in rodents). No acute lethal toxicity has been reported at these doses.

11.2 Dose-dependent hepatotoxicity (the "double-edged sword")

A critically important safety observation is the paradoxical, dose-dependent hepatotoxicity of Schisandrin B at high concentrations. Ip et al. (2015) reported that Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages at high concentrations in vitro [30]. This "double-edged sword" profile, in which the compound is hepatoprotective at low to moderate doses and hepatotoxic at high doses, has been characterized in the context of nonalcoholic fatty liver disease and represents a major safety consideration for dose selection in any clinical translation program [30].

The mechanistic basis for the high-dose hepatotoxicity is not fully elucidated but may involve excessive pro-oxidant activity (the same transient ROS elevation that drives Nrf2 activation at low doses exceeding the cellular buffering capacity at high doses), excessive autophagy induction beyond the protective threshold, or direct mitochondrial toxicity at supratherapeutic concentrations.

11.3 Repeated-dose toxicology

Preclinical concomitant toxicokinetic studies of Schisandrin B in dogs demonstrated notable dose-dependent plasma accumulation during repeated administration, with the degree of accumulation increasing with dose [31]. This finding suggests a narrow therapeutic window for chronic dosing and supports the need for careful dose escalation and pharmacokinetic monitoring in any future human studies.

11.4 Organ toxicity considerations

Potential adverse effects on the functions of the liver and kidneys at supratherapeutic exposures have been identified as safety concerns in preclinical risk assessments [31]. Immune system effects at high doses have also been flagged as a potential concern based on the macrophage toxicity observations of Ip et al. [30].

11.5 Reproductive and developmental toxicity

Reproductive and developmental toxicity data for isolated Schisandrin B are not available in the published literature. The traditional use of Schisandra fruit during pregnancy in East Asian medicine has not been systematically evaluated for safety; standard precautionary guidance would advise against use during pregnancy and lactation pending formal reproductive toxicology studies.

11.6 Genotoxicity and carcinogenicity

Formal genotoxicity and carcinogenicity studies of isolated Schisandrin B have not been published. The compound's antioxidant activity at therapeutic doses would be expected to reduce oxidative DNA damage, but the transient pro-oxidant mechanism of Nrf2 activation raises a theoretical concern about genotoxic potential at high doses that has not been experimentally addressed.

11.7 Drug interaction safety

The potent CYP3A and P-glycoprotein inhibition by Schisandrin B (Section 10) is a significant safety consideration. Unintended elevation of the plasma concentration of narrow-therapeutic-index drugs metabolized by CYP3A (tacrolimus, cyclosporine, sirolimus, warfarin, certain chemotherapy agents) could produce serious adverse effects. Investigators administering Schisandrin B to animals receiving concurrent pharmacotherapy should monitor drug levels and adjust doses accordingly.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five hepatoprotective, antioxidant, or Nrf2-activating compounds against Schisandrin B, evaluated against five competency standards: novelty, effect size, promising potential (current developmental state and trajectory), side-effect profile, and overall validation. The five comparators were selected as representative compounds from distinct structural and mechanistic classes that share overlapping pharmacological territory with Schisandrin B in hepatoprotective and cytoprotective applications.

12.1 Silymarin (Silibinin)

Mechanism: Silymarin is a complex of flavonolignans (silibinin A, silibinin B, isosilibinin A, isosilibinin B, silychristin, silydianin) extracted from the seeds of *Silybum marianum* (milk thistle). The principal active component, silibinin, acts as a hepatoprotective agent through multiple mechanisms: free radical scavenging, membrane stabilization, inhibition of lipid peroxidation, upregulation of hepatocyte protein synthesis through RNA polymerase I stimulation, and anti-inflammatory activity through inhibition of NF- κ B and 5-lipoxygenase [39].

Novelty: Low. Silymarin is the historical reference standard for plant-derived hepatoprotective agents, with clinical use dating to the 1960s and extensive literature spanning more than 50 years. The mechanism is well characterized and is not novel in the current pharmacological landscape.

Effect size: Moderate. Meta-analyses of silymarin in chronic liver disease have reported modest reductions in serum transaminases and histological inflammation scores, with inconsistent effects on hard clinical endpoints (mortality, transplant-free survival). The HALT-C trial (a major NIH-funded study) did not demonstrate significant benefit of silymarin in hepatitis C patients who had not responded to interferon therapy.

Promising potential: Moderate. Silymarin is a registered herbal medicine and over-the-counter supplement in many jurisdictions. It is widely used but has not achieved definitive clinical validation for any liver disease indication by modern

regulatory standards.

Side-effect profile: Favorable. Silymarin is generally well tolerated, with mild gastrointestinal effects (nausea, bloating, diarrhea) as the most common adverse events. Serious adverse events are rare. The favorable safety profile is a significant advantage over compounds with narrow therapeutic windows.

Overall validation: Moderate. Extensive clinical use and a large but heterogeneous clinical evidence base. Regulatory validation is incomplete by modern standards.

Comparison to Schisandrin B: Silymarin has a substantially larger clinical evidence base and a more favorable safety profile than Schisandrin B. Schisandrin B has more precisely characterized molecular mechanisms (Nrf2/NF- κ B dual-axis, SIRT1, AMPK) and stronger preclinical efficacy in standardized models. The two compounds act through partially overlapping but distinct mechanisms and could theoretically be combined.

12.2 Sulforaphane

Mechanism: Sulforaphane is an isothiocyanate derived from the hydrolysis of glucoraphanin, a glucosinolate abundant in cruciferous vegetables (broccoli, broccoli sprouts). It is the most potent naturally occurring inducer of the Nrf2/ARE antioxidant pathway, acting through direct modification of Keap1 cysteine residues to release Nrf2 for nuclear translocation [40].

Novelty: Moderate. The Nrf2-inducing mechanism is shared with Schisandrin B, but sulforaphane's direct Keap1 electrophilic modification is mechanistically distinct from Schisandrin B's redox-mediated Nrf2 activation.

Effect size: Strong in preclinical models. Sulforaphane is the benchmark Nrf2 activator and produces robust, dose-dependent induction of phase II enzymes in virtually all tissue types tested. Human clinical trials have demonstrated measurable increases in glutathione S-transferase activity and reductions in biomarkers of oxidative stress, though clinical disease-modifying effects have been modest and inconsistent across indications.

Promising potential: Moderate to high. Sulforaphane and its precursor glucoraphanin are available as dietary supplements and are the subject of active clinical investigation in cancer chemoprevention, autism spectrum disorder, type 2 dia-

betes, and chronic obstructive pulmonary disease. No regulatory approval for any therapeutic indication.

Side-effect profile: Favorable. Gastrointestinal effects (bloating, flatulence) are the principal adverse events. The compound is derived from dietary sources and has an extensive safety record.

Overall validation: Moderate to high. The most extensively studied Nrf2 activator with the largest clinical investigation portfolio, though no regulatory approval.

Comparison to Schisandrin B: Sulforaphane is a more potent and more selective Nrf2 activator than Schisandrin B at the molecular level. Schisandrin B has broader pharmacological activity (NF- κ B suppression, SIRT1 activation, mitochondrial protection, PXR modulation) that sulforaphane does not share. Sulforaphane has a more advanced clinical investigation portfolio; Schisandrin B has stronger hepatoprotective efficacy in standardized preclinical models.

12.3 Bardoxolone Methyl (CDDO-Me)

Mechanism: Bardoxolone methyl is a synthetic triterpenoid derived from oleanolic acid that activates Nrf2 through direct interaction with Keap1 cysteine residues and suppresses NF- κ B through inhibition of IKK-beta [41]. The dual Nrf2/NF- κ B mechanism is mechanistically analogous to Schisandrin B's composite pharmacology, though at substantially higher potency.

Novelty: High. The synthetic triterpenoid class represents a rationally designed optimization of the Nrf2/NF- κ B dual-axis pharmacology that Schisandrin B achieves naturally.

Effect size: Strong in preclinical models and measurable in human clinical trials. Phase 2 trials in chronic kidney disease (BEAM trial) demonstrated significant improvement in estimated glomerular filtration rate. Phase 3 trial (BEACON) in type 2 diabetes and stage 4 chronic kidney disease was terminated due to heart failure and cardiovascular safety events.

Promising potential: Moderate. Development continues for Alport syndrome and other kidney diseases after the BEACON termination. The compound has demonstrated clinical efficacy but carries significant cardiovascular safety concerns.

Side-effect profile: Concerning. The BEACON trial termination was driven by excess heart failure events, fluid retention, and hypertension. Muscle spasms and elevated liver enzymes were additional adverse events. The safety profile represents a significant liability relative to naturally derived alternatives.

Overall validation: Moderate. Demonstrated clinical efficacy in Nrf2-dependent endpoints but limited by cardiovascular safety. The most clinically advanced Nrf2 activator but with the most significant safety concerns.

Comparison to Schisandrin B: Bardoxolone methyl is substantially more potent than Schisandrin B at both Nrf2 and NF-kB targets. The cardiovascular safety signal of bardoxolone methyl has not been observed with Schisandrin B in preclinical studies, though Schisandrin B has not been studied at equivalent potency-adjusted doses. Schisandrin B's lower potency may confer a wider therapeutic window, though this hypothesis has not been formally tested.

12.4 Curcumin

Mechanism: Curcumin is a polyphenolic diarylheptanoid from *Curcuma longa* (turmeric). It exhibits pleiotropic anti-inflammatory and antioxidant activity through multiple mechanisms: NF-kB suppression, Nrf2 activation, COX-2 inhibition, STAT3 modulation, and direct free radical scavenging [42]. The pleiotropic profile is analogous to Schisandrin B.

Novelty: Low. Curcumin is one of the most extensively studied natural products in biomedical research, with more than 20,000 published studies. The mechanisms are thoroughly characterized and are not novel.

Effect size: Inconsistent. Despite the massive preclinical literature demonstrating efficacy in virtually every disease model, clinical translation has been limited by extremely poor oral bioavailability (less than 1 percent), rapid metabolism, and consequent inability to achieve pharmacologically active concentrations in vivo. Clinical trials have produced mixed results across hepatic, inflammatory, oncological, and neurological indications.

Promising potential: Low to moderate. The bioavailability limitation has been the dominant obstacle. Enhanced-bioavailability formulations (phytosomal, nanoparticle, amorphous solid dispersion) have improved pharmacokinetic performance but have not yet produced definitive clinical efficacy.

Side-effect profile: Favorable. Curcumin is generally well tolerated, with gastrointestinal effects as the most common adverse events. Rare hepatotoxicity has been reported with some turmeric supplements, though the causative role of curcumin versus contaminants remains debated.

Overall validation: Low to moderate. Immense preclinical literature but disappointing clinical translation due to bioavailability limitations. Often cited as an example of the gap between preclinical promise and clinical reality for natural products.

Comparison to Schisandrin B: Both compounds exhibit pleiotropic pharmacology through overlapping mechanisms (Nrf2, NF-kB, antioxidant). Schisandrin B has substantially better oral bioavailability (19 to 55 percent vs. less than 1 percent for curcumin) and more consistent preclinical efficacy, particularly in hepatoprotective models. Curcumin has a much larger (though inconsistent) clinical evidence base.

12.5 Ursodeoxycholic Acid (UDCA)

Mechanism: Ursodeoxycholic acid is a secondary bile acid that acts as a hepatoprotective agent through multiple mechanisms: replacement of hydrophobic, hepatotoxic bile acids in the bile acid pool; stabilization of hepatocyte membranes; choleretic activity promoting bile flow; anti-apoptotic effects through reduction of mitochondrial membrane permeability; immunomodulatory effects on hepatic lymphocytes; and modest antioxidant activity [43].

Novelty: Low. UDCA has been used clinically since the 1970s and is a well-established hepatoprotective agent with a defined mechanism.

Effect size: Strong in established indications. UDCA is the only pharmacotherapy with demonstrated disease-modifying efficacy in primary biliary cholangitis (PBC), producing biochemical response (normalization or significant reduction of alkaline phosphatase) in approximately 50 to 70 percent of patients and improved transplant-free survival. Efficacy in primary sclerosing cholangitis, nonalcoholic steatohepatitis, and intrahepatic cholestasis of pregnancy has also been demonstrated, with varying levels of evidence.

Promising potential: High. UDCA is a regulatory-approved medicine for PBC in essentially all major jurisdictions, with established clinical efficacy and a decades-long safety record.

Side-effect profile: Favorable. The principal adverse event is dose-dependent diarrhea. Serious adverse events are rare at approved doses.

Overall validation: High. The gold-standard hepatoprotective agent with regulatory approval, demonstrated disease-modifying clinical efficacy, and a favorable long-term safety profile.

Comparison to Schisandrin B: UDCA has dramatically greater clinical validation and regulatory status than Schisandrin B. The mechanisms are largely non-overlapping: UDCA acts primarily on bile acid composition and hepatocyte membrane stability, while Schisandrin B acts on Nrf2/NF- κ B transcriptional regulation and mitochondrial antioxidant defense. The two agents could theoretically be complementary in combination, particularly for cholestatic liver diseases where Schisandrin B's PXR-mediated bile acid modulation may augment UDCA's choleretic effects.

12.6 Comparator summary

The five comparator compounds span a range of clinical maturity, mechanistic specificity, and safety profiles. **Silymarin** is the historical plant-derived hepatoprotective standard with extensive but inconsistent clinical evidence and a favorable safety profile. **Sulforaphane** is the benchmark Nrf2 activator with the most active clinical investigation program among dietary-derived compounds. **Bardoxolone methyl** is the most potent synthetic Nrf2/NF- κ B dual-axis activator but carries significant cardiovascular safety concerns. **Curcumin** has the largest research literature of any natural product but suffers from poor bioavailability that has limited clinical translation. **UDCA** is the gold-standard hepatoprotective agent with regulatory approval and demonstrated disease-modifying efficacy.

Schisandrin B occupies a distinctive position in this comparator landscape. It combines a well-characterized dual-axis Nrf2/NF- κ B mechanism with additional SIRT1, AMPK, PXR, and mitochondrial protective activities that none of the individual comparators replicate in full. Its oral bioavailability (19 to 55 percent) is substantially superior to curcumin and adequate for pharmacological activity. Its pre-clinical hepatoprotective efficacy across multiple injury models is among the most consistent in the plant-derived compound space. However, the absence of human clinical trials, the paradoxical high-dose hepatotoxicity signal, the dose-dependent plasma accumulation in preclinical toxicology, and the potent CYP3A/P-glycoprotein inhibition represent substantial translational challenges that must be addressed before the compound can advance beyond preclinical status.

The principal practical question for the developmental positioning of Schisandrin B is whether its multi-targeted mechanism is an advantage (producing robust, multi-pathway hepatoprotection) or a liability (increasing the complexity of dose optimization, drug interactions, and safety monitoring). The preclinical evidence base supports the former interpretation within the studied dose range; the high-dose hepatotoxicity and the CYP3A interaction profile urge caution at the translational interface.

13. References

1. Opletal L, Sovova H, Bartlova M. Dibenzo[a,c]cyclooctadiene lignans of the genus *Schisandra*: importance, isolation and determination. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2004;812(1-2):357-371.
2. Lu Y, Chen DF. Analysis of *Schisandra chinensis* and *Schisandra sphenanthera*. *J Chromatogr A.* 2009;1216(11):1980-1990.
3. Panossian A, Wikman G. Pharmacology of *Schisandra chinensis* Bail.: an overview of Russian research and uses in medicine. *J Ethnopharmacol.* 2008;118(2):183-212.
4. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science Press; 2020.
5. Szopa A, Kokotkiewicz A, Luczkiewicz M, Ekiert H. *Schisandra* lignans production regulated by different bioreactor type. *J Biotechnol.* 2017;247:11-17.
6. Liu GT. Bicyclol: a novel anti-hepatitis drug with hepatocyte protective mechanism. *Hepatol Int.* 2009;3(Suppl 1):S28-S32.
7. Leong PK, Ko KM. Schisandrin B: a double-edged sword in nonalcoholic fatty liver disease. *Oxid Med Cell Longev.* 2016;2016:6171658.
8. Nasser MI, Zhu S, Chen C, Zhao M, Huang H, Zhu P. A comprehensive review on Schisandrin B and its biological properties. *Oxid Med Cell Longev.* 2020;2020:2172740.
9. Checker R, Patwardhan RS, Sharma D, et al. Schisandrin B exhibits anti-inflammatory activity through modulation of the redox-sensitive transcription factors Nrf2 and NF-kappaB. *Free Radic Biol Med.* 2012;53(7):1421-1430.
10. Ip SP, Poon MK, Che CT, Ng KH, Kong YC, Ko KM. Schisandrin B protects against carbon tetrachloride toxicity by enhancing the mitochondrial glutathione redox status in mouse liver. *Free Radic Biol Med.* 2000;29(10):989-999.
11. Chen Q, Zhang H, Cao Y, et al. Schisandrin B alleviates lipid metabolism disorders and apoptosis of MAFLD via modulation of PPARgamma-PCK1 and caspase-3 signaling pathways. *Front Pharmacol.* 2023;14:1129283.

12. Wei M, Liu G, Liu Y, et al. Protective effects of Schisandrin B against D-GalN-induced cell apoptosis in human hepatocyte (L02) cells via modulating Bcl-2 and Bax. *Biomed Res Int.* 2022;2022:4938976.
13. Zhang Q, Liu J, Li R, et al. Study on the role of Schisandrin B in ameliorating hepatic ischemia-reperfusion injury by modulating hepatocyte autophagy. *Iran J Pharm Res.* 2023;22(1):e137270.
14. Li X, Zhang Y, Chen S, et al. Schisandrin B targets PXR to enhance bile acid metabolism and alleviate ANIT-induced cholestatic liver injury via dual pathways. *Phytomedicine.* 2025;138:156378.
15. Zhu P, Li J, Fu X, Yu Z. Schisandrin B attenuates CCl4-induced liver fibrosis in rats by regulation of Nrf2-ARE and TGF-beta/Smad signaling pathways. *Drug Des Devel Ther.* 2017;11:2179-2191.
16. Zhang M, Liu Y, Li H, et al. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway. *Metabolism.* 2020;111:154345.
17. Liu X, Ni W, Zhang M, et al. Schisandrin B diet inhibits oxidative stress to reduce ferroptosis and lipid peroxidation to prevent pirarubicin-induced hepatotoxicity. *Biomed Res Int.* 2022;2022:5623024.
18. Thandavarayan RA, Giridharan VV, Arumugam S, et al. Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. *PLoS One.* 2015;10(3):e0119214.
19. Li X, Zhang Y, Wang J, et al. In vivo and in vitro investigations of Schisandrin B against angiotensin II induced ferroptosis and atrial fibrosis by regulation of the SIRT1 pathway. *Sci Rep.* 2025;15(1):5687.
20. Wang Y, Chen Z, Li X, et al. Schisandrin B regulates the SIRT1/PI3K/Akt signaling pathway to ameliorate Ang II-infused cardiac fibrosis. *J Cardiovasc Pharmacol.* 2025;85(4):312-324.
21. Giridharan VV, Thandavarayan RA, Sato S, Ko KM, Konishi T. Prevention of scopolamine-induced memory deficits by schisandrin B, an antioxidant lignan from *Schisandra chinensis* in mice. *Free Radic Res.* 2011;45(8):950-958.

22. Giridharan VV, Thandavarayan RA, Bhilwade HN, Ko KM, Watanabe K, Konishi T. Schisandrin B ameliorates ICV-infused amyloid beta induced oxidative stress and neuronal dysfunction through inhibiting RAGE/NF-kappaB/MAPK and up-regulating HSP/Beclin expression. *PLoS One*. 2015;10(11):e0142483.
23. Xian H, Feng W, Zhang J. Schisandrin B suppresses colon cancer growth by inducing cell cycle arrest and apoptosis: molecular mechanism and therapeutic potential. *ACS Pharmacol Transl Sci*. 2024;7(5):1505-1517.
24. Chen X, Li Y, Zhang H, et al. Schisandrin B downregulates exosomal fibronectin 1 expression to inhibit hepatocellular carcinoma growth. *Cancer Cell Int*. 2024;24:156.
25. Li W, Qu H, Tao Z, et al. Investigation of pharmacokinetics, tissue distribution and excretion of schisandrin B in rats by HPLC-MS/MS. *J Pharm Biomed Anal*. 2017;145:735-742.
26. Mu Y, Zhang J, Zhang S, et al. Pharmacokinetics and tissue distribution study of schisandrin B in rats by ultra-fast liquid chromatography with tandem mass spectrometry. *J Pharm Biomed Anal*. 2013;78-79:136-140.
27. Qin XL, Chen X, Wang Y, et al. In vivo effect of Schisandrin B on cytochrome P450 enzyme activity. *Phytomedicine*. 2014;21(6):840-845.
28. Song JH, Cui L, An LB, et al. Inhibitory effects of Schisandra lignans on cytochrome P450s and uridine 5'-diphospho-glucuronosyl transferases in human liver microsomes. *Chem Biol Interact*. 2021;338:109393.
29. Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. *Methods Find Exp Clin Pharmacol*. 2006;28(1):25-29. (Schisandra-tacrolimus interaction reported in: Xin HW, et al. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. *Br J Clin Pharmacol*. 2007;64(4):469-475.)
30. Ip SP, Leong PK, Leung PC, Ko KM. Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity. *Int J Mol Med*. 2015;36(1):155-162.
31. Li X, Wang Y, Zhang H, et al. Preclinical concomitant toxicokinetic study of Schisandrin B by HPLC-MS/MS. *Biomed Chromatogr*. 2025;39(5):e70068.

32. Ko KM, Ip SP, Poon MK, et al. Effect of a lignan-enriched fructus Schisandrae extract on hepatic glutathione status in rats: protection against carbon tetrachloride toxicity. *Planta Med.* 1995;61(2):134-137.
33. Xu M, Liu J, Zhang Y, et al. Schisandrin B improves mitochondrial function and inhibits HT22 cell apoptosis by regulating Sirt3 protein. *J Membr Biol.* 2025;258(2):145-156.
34. Yuan Y, Zhang H, Sun F, et al. HPLC-MS/MS-mediated analysis of the pharmacokinetics, bioavailability, and tissue distribution of schisandrol B in rats. *Front Pharmacol.* 2021;12:652376.
35. Xu Y, Liu Z, Sun J, et al. Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. *PLoS One.* 2011;6(12):e28335.
36. Chen F, Zhang H, Zhao Y, et al. Schisandrin B attenuates airway inflammation by regulating the NF-kappaB/Nrf2 signaling pathway in mouse models of asthma. *J Immunol Res.* 2021;2021:8029963.
37. Lv X, Liu D, Hou J, Dong P, Zhan L, Wang L. Schisandrin B inhibits LPS-induced inflammatory response in human umbilical vein endothelial cells by activating Nrf2. *Int Immunopharmacol.* 2017;49:142-150.
38. Lee K, Kang M, Yoo H, et al. Protective effects of Schisandrin B on cigarette smoke-induced airway injury in mice through Nrf2 pathway. *J Pharmacol Sci.* 2018;136(2):95-103.
39. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. *Drugs.* 2001;61(14):2035-2063.
40. Dinkova-Kostova AT, Fahey JW, Kostov RV, Kensler TW. KEAP1 and done? Targeting the NRF2 pathway with sulforaphane. *Trends Food Sci Technol.* 2017;69(Pt B):257-269.
41. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. *N Engl J Med.* 2011;365(4):327-336.
42. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol.* 2009;41(1):40-59.

43. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1 Suppl):S25-S37.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Schisandrin B has not been evaluated in human clinical trials as an isolated compound; all pharmacological and safety data derive from preclinical studies and from clinical experience with Schisandra chinensis extracts and the semi-synthetic derivative bifendate. The compound exhibits dose-dependent paradoxical hepatotoxicity at high concentrations and potent CYP3A/P-glycoprotein inhibition; investigators should exercise caution in dose selection and in combination studies. Investigators should obtain analytical confirmation of identity and purity on every lot.